淋巴瘤诊断专家病理复核的影响:法国淋巴病理网络患者研究
研究前瞻性评估法国淋巴病理网络专家复核淋巴瘤诊断的临床影响。2010年1月至2013年12月,42,145份样本经实时专家复核,19.7%患者诊断改变,17.4%影响临床管理;临时诊断寻求二次意见者改变率37.8%,正式诊断者3.7%。
要点
- 42,145份样本中,19.7%诊断改变,17.4%对患者管理有影响。
- 临时诊断寻求专家二次意见者诊断改变率37.8%,正式诊断者3.7%。
- 最常见差异为淋巴瘤亚型误分类(41.3%),小B细胞淋巴瘤实体误分类占12.3%。
核心结论
- 研究提供西方国家淋巴瘤实体分布的最大规模描述,并强调专家复核在部分患者中显著促进精确诊断和优化临床管理。
研究设计与样本
- 前瞻性研究,2010年1月至2013年12月法国淋巴病理网络实时专家复核42,145份新诊断或疑似淋巴瘤患者样本,按2008年WHO分类。
主要发现
- 42,145份样本包括36,920例新诊断成熟淋巴瘤、321例前体淋巴样肿瘤、314例髓系疾病、200例非造血系统肿瘤和4,390例良性病变。
- 常见非皮肤成熟淋巴瘤:弥漫大B细胞淋巴瘤32.4%、滤泡性淋巴瘤15.3%、经典霍奇金淋巴瘤13%、外周T细胞淋巴瘤6.3%(其中血管免疫母细胞性T细胞淋巴瘤2.3%最常见)、黏膜相关淋巴组织淋巴瘤5.8%。
- 19.7%患者诊断改变,估计17.4%患者临床管理受影响;临时诊断寻求二次意见者37.8% vs 正式诊断者3.7%,差异显著。
- 最常见差异为淋巴瘤亚型误分类41.3%,其中小B细胞淋巴瘤实体误分类12.3%;良恶性淋巴样病变间改变少于2%。
- 轻微改变2.3%,主要为滤泡性淋巴瘤分级错误和弥漫大B细胞淋巴瘤亚型误分类。
关键数值与推荐
- 诊断改变率19.7%,估计影响临床管理率17.4%。
- 临时诊断寻求二次意见者诊断改变率37.8%,正式诊断者3.7%。
- 淋巴瘤亚型误分类41.3%,小B细胞淋巴瘤实体误分类12.3%。
- 良恶性淋巴样病变间改变少于2%,轻微改变2.3%。
临床怎么用
- 原文结论指出专家复核在部分患者中显著促进精确淋巴瘤诊断和优化临床管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the Lymphopath Network. Changes in diagnosis between referral and expert review were classified as major or minor according to their potential impact on patient care. Results The 42,145 reviewed samples comprised 36,920 newly diagnosed mature lymphomas, 321 precursor lymphoid neoplasms, 314 myeloid disorders, and 200 nonhematopoietic neoplasms, with 4,390 benign lesions. There were 4,352 cutaneous and 32,568 noncutaneous lymphomas. The most common mature noncutaneous lymphomas were diffuse large B-cell lymphomas (32.4%), follicular lymphomas (15.3%), classic Hodgkin lymphomas (13%), peripheral T-cell lymphomas (6.3%) of which angioimmunoblastic T-cell lymphomas (2.3%) were the most frequent, and mucosa-associated lymphoid tissue lymphomas (5.8%). A diagnostic change between referral and expert review occurred in 19.7% of patients, with an estimated impact on patient care for 17.4% of patients. This rate was significantly higher for patients sent with a provisional diagnosis seeking expert second opinion (37.8%) than for patients sent with a formal diagnosis (3.7%). The most frequent discrepancies were misclassifications in lymphoma subtype (41.3%), with 12.3% being misclassifications among small B-cell lymphoma entities. Fewer than 2% of changes were between benign and malignant lymphoid conditions. Minor changes (2.3%) mostly consisted of follicular lymphoma misgrading and diffuse large B-cell lymphoma subtype misclassification. Conclusion To our knowledge, this study provides the largest ever description of the distribution of lymphoma entities in a western country and highlights how expert review significantly contributes to a precise lymphoma diagnosis and optimal clinical management in a proportion of patients.
引用
- Laurent C, Baron M, Amara N, et al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J Clin Oncol. 2017. PMID: 28459613. doi:10.1200/JCO.2016.71.2083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。